<DOC>
	<DOCNO>NCT00311766</DOCNO>
	<brief_summary>The purpose study investigate treatment enhance heal acute chronic nonhealing cutaneous wound , erosion experience patient Epidermolysis Bullosa ( EB ) , know activity thymosin beta 4 ( Tβ4 ) . Funding Source - FDA Office Orphan Product Development ( OOPD ) .</brief_summary>
	<brief_title>A Phase 2 Study Effect Thymosin Beta 4 Wound Healing Patients With Epidermolysis Bullosa</brief_title>
	<detailed_description>EB group genetic disease characterize skin-blistering lesion-formation minor trauma skin . This family disorder , inherit , range severity mild severely disable life-threatening . Tβ4 synthetically-produced copy naturally-occurring 43 amino acid peptide wound heal anti-inflammatory property up-regulate expression laminin-5 .</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<criteria>Informed Consent form sign patient patient 's legal representative ; also , patient age majority capable provide assent , sign assent patient Diagnosis junctional dystrophic EB . Patients present HallopeauSiemens subtype may enrol . At least one active , unroofed EB erosion limb trunk . Lesion size 5 50 cm2 , inclusive . Stable lesion present 1460 day enrollment . More one member family enrol long member treat different cohort assurance study medication share . No clinically significant abnormality ( Grade 2 high National Cancer Institute [ NCI ] toxicity scale ) Screening laboratory test , except follow specific laboratory threshold result : albumin must 2 g/dL high ; hemoglobin must 8 g/dL high . Clinical evidence local infection index ( target ) lesion . Use investigational drug within 30 day enrollment . Use immunotherapy cytotoxic chemotherapy within 60 day enrollment . Use systemic topical steroidal therapy within 30 day enrollment.Inhaled steroid allow . Use systemic antibiotic within 7 day enrollment . Current former malignancy . Arterial venous disorder result ulcerated wound . Diabetes mellitus . Pregnancy breastfeed study . ( A serum pregnancy test perform Screening female patient childbearing potential . )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Epidermolysis Bullosa</keyword>
	<keyword>cutaneous wound-healing</keyword>
	<keyword>chronic wound-healing</keyword>
	<keyword>Thymosin Beta 4</keyword>
	<keyword>laminin-5</keyword>
</DOC>